- Report
- November 2023
- 630 Pages
Global
From €9031EUR$9,500USD£7,723GBP
- Report
- January 2022
- 200 Pages
Global
From €7130EUR$7,500USD£6,097GBP
- Report
- May 2020
- 482 Pages
Global
From €9031EUR$9,500USD£7,723GBP
- Report
- August 2018
- 16 Pages
Global
From €9506EUR$10,000USD£8,130GBP
- Report
- August 2018
- 22 Pages
Global
From €9506EUR$10,000USD£8,130GBP
- Report
- April 2021
- 191 Pages
Global
€20914EUR$22,000USD£17,885GBP
- Report
- January 2019
- 35 Pages
Global
From €951EUR$1,000USD£813GBP
Alecensa (Alectinib) is a prescription medication used to treat certain types of non-small cell lung cancer (NSCLC). It is a type of targeted therapy, which works by blocking the activity of a protein called anaplastic lymphoma kinase (ALK). This protein is found in some types of NSCLC and is thought to be involved in the growth and spread of cancer cells. Alecensa is used to treat NSCLC that has spread to other parts of the body and is caused by a certain type of genetic change (ALK-positive). It is usually given after other treatments, such as chemotherapy, have been tried without success.
Alecensa is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2015. It is currently the only ALK inhibitor approved for the treatment of ALK-positive NSCLC. It is available in both capsule and intravenous (IV) forms.
The Alecensa market is highly competitive, with several companies offering similar treatments. These include Pfizer, Merck, AstraZeneca, and Roche. Other companies, such as Novartis and Eli Lilly, are also developing ALK inhibitors for the treatment of NSCLC. Show Less Read more